AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$24.40
+$0.42 (+1.75%) 11:28 AM ET
Prev closePrevC$23.98
OpenOpen$23.99
Day highHigh$24.44
Day lowLow$23.66
VolumeVol63,333
Avg volAvgVol410,921
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$920.31M
EV/Sales
8.90
P/E ratio
-14.19
FY Revenue
$101.96M
EPS
-1.72
Gross Margin
88.90%
Div yield
0.00%
Sector
Healthcare
AI report sections
BULLISH
CBLL
CeriBell, Inc.
CeriBell exhibits strong medium- to long-horizon price appreciation alongside ongoing operating losses and negative free cash flow. Valuation multiples such as P/S and EV/Sales appear elevated relative to current profitability and cash generation, while the balance sheet shows low leverage and substantial liquidity. Technical indicators point to bullish momentum with recent breakout characteristics, set against heightened volatility and a moderate level of short interest.
AI summarized at 12:39 PM ET, 2026-04-15
AI summary scores
INTRADAY:63SWING:67LONG:44
Volume vs average
Intraday (cumulative)
−62% (Below avg)
Vol/Avg: 0.38×
RSI
68.37(Strong)
Strong (60–70)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.06 Signal: 0.05
Short-Term
-0.04 (Weak)
MACD: 1.29 Signal: 1.33
Long-Term
+0.15 (Strong)
MACD: 1.74 Signal: 1.59
Intraday trend score
60.29
LOW50.29HIGH60.29
Latest news
CBLL•3 articles•Positive: 3Neutral: 0Negative: 0
PositiveGlobeNewswire Inc.• Na
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.
The company is expanding its market presence with 680+ hospital deployments and has attracted experienced executives to its board. The appointments of high-profile leaders from successful medtech exits and major health systems signal confidence in the company's growth trajectory and market leadership in point-of-care brain monitoring.
PositiveGlobeNewswire Inc.• Jane Chao, Ph.D.
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Ceribell obtained FDA 510(k) clearance for its ClarityⓇ algorithm, becoming the first AI-powered point-of-care EEG technology capable of detecting electrographic seizures across all patient ages, from pre-term neonates to adults.
Achieved significant FDA regulatory milestone, expanded technological capabilities, addressed critical unmet medical need in neonatal seizure detection
PositiveGlobeNewswire Inc.• Ceribell, Inc.
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Medical technology company Ceribell announced the appointment of Erica Rogers to its Board of Directors, bringing over three decades of healthcare leadership experience to help expand nationwide access to their point-of-care EEG system.
Company is expanding leadership with an experienced executive, demonstrating strategic growth and potential for innovation
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
